Blueprint Medicines

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$128,184
$138,157
$96,116
$71,957
Gross Profit
126,252
126,947
88,115
70,166
EBITDA
-33,374
-39,428
-74,013
-103,579
EBIT
-37,237
-43,045
-78,823
-105,110
Net Income
-56,276
-49,994
89,136
-110,918
Net Change In Cash
128,184
138,157
96,116
71,957
Free Cash Flow
-13,662
-50,641
-102,617
-83,601
Cash
89,356
54,771
113,326
71,286
Basic Shares
63,381
62,854
63,802
60,890

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$249,380
$204,036
$180,080
$793,735
Gross Profit
224,919
186,223
162,146
793,310
EBITDA
-474,612
-537,518
-641,981
308,707
EBIT
-486,277
-557,617
-654,766
296,357
Net Income
-506,984
-557,517
-644,085
313,882
Net Change In Cash
249,380
204,036
180,080
793,735
Cost of Revenue
-90,008
-473,797
570,545
Free Cash Flow
-452,909
-511,196
-559,894
383,876
Cash
71,286
119,709
209,948
684,636
Basic Shares
60,558
59,642
58,518
56,168

Earnings Calls

Quarter EPS
2024-09-30
-$0.89
2024-06-30
-$0.80
2024-03-31
$1.40
2023-12-31
-$1.82